Primary signet ring cell carcinoma of the cervix: A case report and review of the literature  by Sal, Veysel et al.
P
r
V
O
a
b
a
A
R
R
A
A
K
S
P
C
I
C
1
e
a
d
m
P
m
r
c
a
2
v
p
a
h
2
cCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 21 (2016) 1–5
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
journa l h omepage: www.caserepor ts .com
rimary  signet  ring  cell  carcinoma  of  the  cervix:  A  case  report  and
eview  of  the  literature
eysel  Sala, Ilker  Kahramanoglua,∗,  Hasan  Turana, Nedim  Tokgozoglua, Tugan  Besea,
vgu  Aydinb,  Fuat  Demirkirana, Macit  Arvasa
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Medical Faculty, Istanbul University, Turkey
Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University, Turkey
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 January 2016
eceived in revised form 27 January 2016
ccepted 1 February 2016
vailable online 6 February 2016
eywords:
ignet cell
rimary
ervical
a  b  s  t  r  a  c  t
INTRODUCTION:  Primary  signet  cell carcinoma  of  the  cervix  has  been  reported  only  in  18 cases  to  date.
PRESENTATION  OF  CASE:  A 48-year-old  woman  was seen  at our  Gynecologic  Oncology  Unit,  because  she
complained  postcoital  bleeding  during  the  last  three  months.  She  had  1–2 cm cervical  mass,  originating
from  the endocervical  canal.  A biopsy  revealed  a signet  ring  cell-type  adenocarcinoma.  Suspected  primary
sites were  excluded  after  gastroscopy,  colonoscopy  and  mammography.  The  patient  underwent  a  laparo-
scopic  type-3  radical  hysterectomy  with  bilateral  salpingo–oophorectomy,  pelvic lymph  node  dissection
and  paraaortic  lymph  node  dissection  with  a presumed  diagnosis  of  primary  signet  ring cell  carcinoma  of
the cervix.  Microscopically,  the  tumour  consisted  of  70%  signet  ring  cell  type  and  30%  endocervical  ade-
nocarcinoma.  She  did not  receive  any  adjuvant  treatment.  Follow-up  at 18  months  after  surgery  showedmmunohistochemical
ytokeratin
no  evidence  of  recurrence.
DISCUSSION: Nineteenth  case  of a  primary  signet  ring  cell carcinoma  of  the  cervix  was  presented.  Immuno-
histochemical  studies  and  HPV  DNA positivity  may  help  in  diagnosis.
CONCLUSION:  It is  crucial  to  differentiate  primary  tumour  from  metastatic  signet  cell  carcinoma,  while
treatment  and  prognosis  differ  signiﬁcantly.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Pure or predominantly signet-ring cell carcinoma of the cervix is
xtremely rare in the literature. In total, 18 cases of primary cervical
denocarcinoma containing signet-ring cells have been reported to
ate [1]. The infrequency with which it is encountered makes pri-
ary signet-ring cell carcinoma of the cervix a diagnostic challenge.
ossible metastasis from any site should be excluded, as manage-
ent and prognosis vary between metastatic and primary signet
ing cell carcinomas of the cervix.
Herein, we report a case of primary predominantly signet ring
ell carcinoma of the cervix with immunohistochemical ﬁndings
nd review the literature.
. Case reportA 48-year-old, gravida 5, para 3 woman with post-coital
aginal bleeding during the last 3 months was  seen in our hos-
ital. Her body mass index was 24 and she had no signiﬁcant
∗ Corresponding author at: Cerrahpasa Medical Faculty, Department of Obstetrics
nd Gynecology, Division of Gynecologic Oncology Fatih, Istanbul, Turkey.
E-mail address: ilkerkahramanoglu@hotmail.com (I. Kahramanoglu).
ttp://dx.doi.org/10.1016/j.ijscr.2016.02.007
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
medical or family history. A pelvic examination revealed a 1–2 cm
cervical mass, which appeared to originate from endocervical
canal. A biopsy revealed a signet ring cell-type adenocarcinoma.
Laboratory studies, including cancer antigen 125 (CA-125), car-
cinogenic antigen (CA 19-9), cancer antigen 15–3 (CA 15-3),
carcinoembriogenic antigen (CEA), and alpha-fetoprotein (AFP),
were within normal limits. Magnetic resonance imaging (MRI)
showed a 1.7 × 1.5-cm cervical mass with a homogeneous inten-
sity on T1-weighted images and a heterogeneous intensity on
T2-weighted images (Fig. 1). Increased FDG uptake on the positron
emission tomography (PET)/computed tomography (CT) images
were found for the cervical mass (SUVmax: 13.5). A gastroscopy
and colonoscopy were performed to reveal the possible primary
site of the tumour, however, both did not the site. In addi-
tion, her preoperative mammogram was  negative. The patient
underwent a laparoscopic type-3 radical hysterectomy with bilat-
eral salpingo–oophorectomy, pelvic lymph node dissection and
paraaortic lymph node dissection with a presumed diagnosis of
primary signet ring cell carcinoma of the cervix. There was no
pathologic ﬁnding in the pelvic cavity or abdomen.Macroscopically, tumour measured 25 × 18 × 13 mm in size and
it was located in ecto- and endocervix. Microscopically, the tumour
consisted of 70% signet ring cell type and 30% endocervical ade-
nocarcinoma. Signet ring cells were within pools of extracellular
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. (A) 1.7 × 1.5-cm cervical mass with a homogeneous intensity on T1-weighted
images and a heterogeneous intensity on T2-weighted images on posterior cervix.
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Fig. 3. The tumor was  composed of signet ring cells within pools of extracellular
mucin. HE ×200.
in ﬁve cases, and it seems to be the most prominent immunohisto-Fig. 2. The tumor was located in ecto-endocervix. HE X50.
ucin (Figs. 2 and 3). The tumour cells had hyperchromatic, eccen-
rically located nuclei and large mucin ﬁlled cytoplasmic vacuoles.
n immunohistochemical study of the tumour showed positivity
or p16 (Fig. 4), CDX-2, MUC1, MUC2 and MUC5AC and negativity
or synaptophysin, chromogranin A and CK–20. The parametrium,
elvic and paraaortic lymph nodes were negative and no lympho-
ascular space invasion was observed.
The patient did not receive postoperative chemotherapy.
ollow-up at 18 months after surgery showed no evidence of recur-
ence.
Written informed consent was obtained from the patient to pub-
ish these data.
. Discussion
Previous cases of primary signet-ring cell carcinoma of the
ervix are presented in Table 1. It is essantial to distinguish a pri-
ary tumour from metastasis when there are signet ring cells in
 carcinoma within cervix. The stomach, colon, breast, appendix,
ladder are possible primary sites for metastasis [1]. Therefore,Fig. 4. The nuclei of tumor cells were diffusely positive for p16. p16 ×400.
further evaluations for other primary sites are mandatory to
exclude metastasis. In addition, an earlier report described some
features in favour of a primary cervical tumour such as a history
of HPV infection, the coexistence of high-grade squamous intraep-
ithelial lesion and adenocarcinoma in situ with an invasive disease
and HPV type 18 in tumour tissue [4]. In our case, a gastroscopy and
colonoscopy were performed and the patient underwent MRI and
PET/CT. However, no other tumour lesion was found. Our patient
had a history of HPV infection, and HPV type 18 was found in her
tumour tissue. HPV type 18 is a well-known risk factor for cervi-
cal adenocarcinomas. Hence, almost all of the reports searching for
HPV-DNA in cases with primary signet ring cell adenocarcinoma of
the cervix including ours showed HPV type 18 positivity, an associa-
tion with HPV type 18 and primary signet ring cell adenocarcinoma
of the cervix may  be easily suggested.
Immunohistochemical studies were performed in most of the
previous studies. However, conﬂicting results have been obtained
(Table 1). Three cases were negative for mammoglobin and no
positive case was reported. Similarly, two cases reported posi-
tive reaction with p16, which may  show an HPV effect on the
tumour. No negative case was reported with p16 immunohisto-
chemical staining. To date, positivity for cytokeratin 7 was shownchemical marker. In a recent study, cervical cytokeratin 7 positivity
was found to be associated with progression of low grade cervical
lesions to high grade cervical lesions [15]. The literature regarding
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Table 1
Summary of cases of primary signet-ring cell carcinoma of the cervix, modiﬁed from Giordano et al. [14].
Author, year Age (years) Presenting symptom Immunohistochemical
studies other than ER
and PR
ER, PR HPV FIGO stage Treatment Outcome
Moll et al., 1990
[2]
50 Postcoital vaginal
bleeding,
menometrorrhagia
NA NA NA III Sx, Rx DOD 10 mo
Mayorga et al., 1997
[3]
Case 1 68 Postcoital vaginal
bleeding
NA NA NA Ib NACT and Sx Disease-free at 35 mo
Case  2 74 Postmenopausal
bleeding
NA NA NA Ib Sx Disease-free at 35 mo
Haswani  et al., 1998
[4]
Case 1 33 Asymptomatic (routine
vaginal smear:
AGC-NOS)
NA ER: − HPV type 18: + III Rx, Chemo DOD 10 mo
Case  2 38 Postcoital vaginal
bleeding
NA ER: −, PR: − NA Ib Sx and Rx Disease-free at 18 mo
Cardosi  et al., 1999
[5]
53 Perimenopausal
bleeding
NA ER: +, PR: + NA Ib Sx, Rx, Chemo Disease-free at 6 mo
Moritani et al., 2004
[6]
29 AUB Positive for CK,
MUC5AC
Negative for vimentin,
MUC2, MUC6
ER: −, PR: − − III Chemo Disease-free at 6 mo
Suaı´rez-  et al., 2007
[7]
80 Vaginal discharge Positive for CK
AE1-AE3, CK 20,
carcinoembryonic
antigen, chromogranin
A, synaptophysin
Negative for vimentin,
S-100 protein, HMB-45,
adrenocorticotropic
hormone, prolactin,
thyroid-stimulating
hormone,
follicle-stimulating
hormone, luteinizing
hormone, growth
hormone, gross
cystic disease ﬂuid
protein 15
NA NA III Rx, Chemo DOD 18 mo
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Table 1 (Continued)
Author, year Age (years) Presenting symptom Immunohistochemical
studies other than ER
and PR
ER, PR HPV FIGO stage Treatment Outcome
Insabato et al., 2007
[8]
46 AUB (cervical polypoid
lesion)
NA NA Ib Sx, Rx, Chemo Disease-free at 3 years
McCluggage et al.,
2007
[9]
(2 cases)
NR NR Positive for CK 7 and
CK 16
Negative for CK 20 and
CDX2
NA NR NR NR NR
Versas  et al., 2009
[10]
Case 1 36 Thromboembolic
events
Positive for p16 and CK
7
Negative for CK 20,
CDX2 and Dpc4
ER: −,  PR: − + IV Chemo Dod 7 weeks
Case  2 43 Metastases of lung and
lymph nodes
Positive for p16 and CK
7
Negative for CK 20,
CDX2 and
mammoglobin
ER: −,  PR: − NA IV Chemo Dod 2 mo
Lowery  et al., 2009
[11]
About 60 Postmenopausal
bleeding
NA NA NA Ib1 Rx and Sx (for
synchronous
endometrial cancer)
Disease-free at >10
years
Balci  et al., 2010
[12]
53 Postmenopausal
bleeding
Positive for CK, p16,
CEA, MUC1, and MUC5.
Negative for CK 20,
GCDFP15, MUC2,
chromogranine,
synaptophysin,
PGP 9.5, CD56,
vimentin,
CDX-2, TTF-1, and
mammaglobin
ER: −,  PR. − HPV type 18: + NR Sx NR
Yoon  et al., 2011
[13]
47 Postcoital vaginal
bleeding
Positive for p53 and Rb NA NA Ib1 Sx Dod 6 mo
Giordano  et al., 2012
[14]
45 Persistent AUB Positive for CK 7,
CA-125, CEA and p16
Negative for vimentin
NA HPV type 18: + IIb Sx NR
Washimi et al., 2015
[1]
31 AUB Positive for MUC2,
CDX2, CEA, CK7
Negative for MUC1,
MUC5AC, MUC6, p53,
CK20, TTF-1, GCDFP-1,
mammoglobin,
chromogranin-1, p16,
HIK1083
ER: −,  PR: − HPV type 18: + Ib1 Sx and chemo Disease-free at 41 mo
Present  case 48 Postcoital vaginal
bleeding
Positive for p16,
CDX-2, MUC1
MUC2, MUC5AC
Negative for
synaptophysin,
chromogranin A, CK20
ER: −,  PR: − HPV type 18: + Ib1 Sx Disease-free at 18 mo
CK: cytokeratin. MUC: mucin. TTF: thyroid transcripton factor. GCDFP: gross cystic disease ﬂuid protein. ER: estrogen receptor. PR: progesteron receptor. NA: not available. Sx: surgery. Rx: radiation therapy. DOD: died of disease.
Mo:  months. NACT: neoadjuvant chemotherapy. Chemo: chemotherapy. AUB: abnormal uterine bleeding. NR: not reported.
 –  O
 of Sur
i
m
b
C
s
c
c
c
r
c
n
m
B
s
l
l
d
o
2
w
w
m
a
a
s
h
o
d
C
F
E
C
f
A
m
t
r
[
[
[
[
[
[
O
T
p
cCASE  REPORT
V. Sal et al. / International Journal
mmunohistochemical staining with MUC  1, MUC  2, MUC  5, chro-
ogranin A and synaptophysin showed different results. Only one
ut 6 cases stained for CK 20 showed negativity. In addition, while
DX2 was shown to be negative in all of four cases that were
tained, for the ﬁrst time, we found positivity. This ﬁnding might be
onsidered as unexpected, since CDX2 is speciﬁcally expressed in
olorectal adenocarcinomas. Based on conﬂicting results, one can
onclude that immunohistochemical studies are not even close to
ejecting or proving the diagnosis of primary signet cell cervical
ancer.
While the data on primary signet cell carcinoma of the cervix is
ot enough to provide a recommendation regarding treatment, we
anaged our patient as having an adenocarcinoma of the cervix.
ecause there were no intermediate (large tumour size, cervical
tromal invasion to the middle or deep one-third, lymphovascu-
ar space invasion) or high risk factors (positive margins, positive
ymph nodes, parametrial involvement) for recurrent disease, we
id not offer any adjuvant treatment.
It is not easy to predict survival because of the small number
f the cases. In two cases with stage IV, patients died of disease in
 months [10]. However, more than 10 years disease-free survival
as reported in a patient with stage IB1 disease. While our case
as staged as IB1, a long-term survival may  be hoped.
In conclusion, it is crucial to differantiate primary from
etastatic signet cell carcinoma of the cervix. If our case had been
ccepted as a metastasis, it would have been stage IV and received
 very different kind of therapy. A clinical examination and imaging
tudies should be performed carefully for this purpose. Immuno-
istochemical studies may  be helpful, especially when the number
f cases increases. In addition, HPV DNA positivity may  conﬁrm the
iagnosis as primary.
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